 |
|
|
| |
Recruitment of Disproportionately Affected Populations in the
PURPOSE 5 Study Evaluating Lenacapavir for PrEP in France and the UK
|
| |
| |
20th EACS Oct 15-18 2025 Paris, France
Lenacapavir 5 PrEP Global Studies
PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis (PrEP) in France and the United Kingdom -
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess the persistence-defined as consistent and continuous use-of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The study has an intentional focus on recruiting participants from groups across France and the United Kingdom that are disproportionally affected by HIV and often underrepresented in clinical trials.
https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-new-clinical-trial-in-europe-to-assess-lenacapavir-for-hiv-prevention-as-part-of-landmark-purpose-program
|
| |
|
|
|
|
|
